Vadhan-Raj, S., Kuderer, N. M., Wun, T., Patel, J., McCrae, K., Zhou, X., … Khorana, A. A. (2021). OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial. In Thrombosis Research (Vol. 200, pp. S12–S12). Elsevier BV. https://doi.org/10.1016/s0049-3848(21)00154-7

Vadhan-Raj, S., N. M. Kuderer, T. Wun, J. Patel, K. McCrae, X. Zhou, U. Vijapurkar, et al. “OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial.” In Thrombosis Research, 200:S12–S12. Elsevier BV, 2021. https://doi.org/10.1016/s0049-3848(21)00154-7.

Vadhan-Raj S, Kuderer NM, Wun T, Patel J, McCrae K, Zhou X, et al. OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial. In: Thrombosis Research. Elsevier BV; 2021. p. S12–S12.

Vadhan-Raj, S., et al. “OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial.” Thrombosis Research, vol. 200, Elsevier BV, 2021, pp. S12–S12. Crossref, doi:10.1016/s0049-3848(21)00154-7.

Vadhan-Raj S, Kuderer NM, Wun T, Patel J, McCrae K, Zhou X, Vijapurkar U, Damaraju CV, Wildgoose P, Lyman GH, Khorana AA. OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial. Thrombosis Research. Elsevier BV; 2021. p. S12–S12.